Deubiquitinases in cancer

// Rongbin Wei 1, * , Xiaodong Liu 2, * , Weixin Yu 3, * , Tianshu Yang 1 , Wenping Cai 1 , Junjun Liu 1 , Xiao Huang 1 , Guo-tong Xu 1 , Shouliang Zhao 3 , Jianhua Yang 1 , Shangfeng Liu 3 1 Department of Ophthalmology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P. R. China 2 Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, P. R. China 3 Department of Stomatology, Huashan Hospital, Fudan University, Shanghai 200040, P. R. China * These authors have contributed equally to this work Correspondence to: Shangfeng Liu, e-mail: liusf23@gmail.com Jianhua Yang, e-mail: jianhuay@gmail.com Shouliang Zhao, e-mail: SLzhao@tongji.edu.cn Keywords: deubiquitinases, cancer, ubiquitylation, inhibitor Received: January 16, 2015 Accepted: April 24, 2015 Published: May 07, 2015 ABSTRACT Deubiquitinases are deubiquitinating enzymes (DUBs), which remove ubiquitin from proteins, thus regulating their proteasomal degradation, localization and activity. Here, we discuss DUBs as anti-cancer drug targets.